

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Bella Vista Hospital</p> <p>2. P.O. Box 1750</p> <p style="text-align: center;">Mayagüez, Puerto Rico 00681</p>	<p style="text-align: center;">In accordance with the application dated January 11, 1999</p> <p>3. License No. 52-25223-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date: December 31, 2002</p> <hr/> <p>5. Docket No. 030-32986</p>
---	---

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material identified in 10 CFR 35.100</p> <p>B. Any byproduct material identified in 10 CFR 35.200</p> <p>C. Iodine 131</p> <p>D. Any byproduct material with a half-life less than 120 days, except iodine 131</p>	<p>7. Chemical and/or physical form</p> <p>A. Any radiopharmaceutical identified in 10 CFR 35.100</p> <p>B. Any radiopharmaceutical identified in 10 CFR 35.200</p> <p>C. Any unsealed form for preparation and administration as specified in §35.300</p> <p>D. Any form for uses described in §35.300 initially distributed in accordance with a specific license issued to Section 32.72 of 10 CFR Part 32 or a specific license issued to the manufacturer by an Agreement State pursuant to equivalent State regulations.</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 55.5 gigabecquerels (1.5 curies)</p> <p>D. As needed</p>
---	--	--

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
52-25223-01

Docket or Reference Number
030-32986

Amendment No. 4

- | | | |
|---|---|--|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>E. Any byproduct material identified in 10 CFR 35.400</p> | <p>7. Chemical and/or physical form</p> <p>E. Any brachytherapy sources identified in 10 CFR 35.400</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>E. Cesium 137 capsule - 37 gigabecquerels (GBq) (1,000 millicuries)
Cesium 137 cells - 18.5 GBq (500 millicuries)
Iridium 192 ribbons - 18.5 GBq (500 millicuries)
Palladium 103 seeds - 25.9 GBq (700 millicuries)
Iodine 125 seeds - 25.9 GBq (700 millicuries)</p> |
|---|---|--|

9. Authorized Use:

- A. Medical use identified in 10 CFR 35.100.
B. Medical use identified in 10 CFR 35.200.
C. and D. Any radiopharmaceutical therapy approved in §35.300.
E. Medical use identified in 10 CFR 35.400.

CONDITIONS

10. Location for use: Bella Vista Hospital
Cerro Las Mesas, Road 349 Km. 2.7
Mayagüez, Puerto Rico 00680.
11. Radiation Safety Officer: **Roberto J. Torres Colón, M.S. and in his absence Aracelis Rivera Serrano, M.D. or Miguel A. Vigo, M.D.**
12. Authorized users:
- A. Aracelis Rivera Serrano, M.D. Medical use described in 10 CFR 35.100, 35.200 and 35.300.
B. Edgar Vázquez-González, M.D. Cardiac function and imaging studies identified in 10 CFR 35.100 and 10 CFR 35.200.
C. Miguel A. Vigo, M.D. Medical use described in 10 CFR 35.100, 35.200, and 35.300.
D. Julio J. Díaz Padilla, M.D. Medical use described in 10 CFR 35.400.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
52-25223-01

Docket or Reference Number
030-32986

Amendment No. 4

13. In addition to the possession limits in item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35 for establishing decommissioning financial assurance.
14. Except as specifically provided otherwise in the license and as provided in 10 CFR 35.51, the licensee shall conduct its program in accordance with statements, representations, and procedures contained in the documents including any enclosures, listed below. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Applications dated (with enclosures):

1. October 15, 1992
2. April 1, 1996 (received)(add Dr. Vigo as authorized user)
3. November 18, 1996 (Add Dr. Díaz, brachytherapy operations)
4. October 23, 1998 (changes in Nuclear Medicine department layout)

B. Letters dated:

1. October 26, 1992 (requesting addition of Dr. Edgar J. Vazquez as an authorized user)
2. November 30, 1992 (response to deficiency letter dated November 17, 1992)
3. May 29, 1996 (add new RSO)
4. January 21, 1997 (brachytherapy equipment to be used & facility floor diagram)
5. February 11, 1997 (details to Dr. Díaz additional training)
6. March 3, 1997 (changes to rad. safety program & instruments cal.)
7. November 3, 1998 (fax) (maximum quantities of Pd 103 and I 125 for 35.400 use)
8. January 11, 1999 (change RSO and in absence RSO's)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

DAVID J. COLLINS

BY

David J. Collins

Region II, Division of Nuclear Materials Safety
61 Forsyth Street, SW, Suite 23T85
Atlanta, GA 30303-8931

DATE

FEB 17 1999